Annex 1 and Quality by Design in Sterile Fill Finish

At CDMO Live Europe in Rotterdam, Eramol Site Director David Cox delivered a technical presentation on the practical application of EU GMP Annex 1 and Quality by Design during the development of a new sterile fill-finish facility.

The presentation explored an important principle: in sterile pharmaceutical manufacturing, quality cannot be inspected into a product at the end of the process. It must be considered from the earliest stages of facility, equipment and process design.

This article summarises several of the central themes from the presentation and considers how Quality by Design can help create a robust, flexible and contamination-controlled environment for the manufacture of sterile investigational medicinal products.

Why EU GMP Annex 1 matters

EU GMP Annex 1 sets out expectations for the manufacture of sterile medicinal products. The revised guidance places particular emphasis on the use of quality risk management, appropriate technologies, contamination prevention and a holistic Contamination Control Strategy, commonly referred to as a CCS.

Its scope extends well beyond the filling operation itself. Annex 1 requires manufacturers to consider the interconnected controls that protect sterile products throughout their manufacture.

These include:

• facility and cleanroom design;
• personnel and material flows;
• utilities and environmental controls;
• equipment selection and qualification;
• cleaning and disinfection;
• barrier technologies;
• process design;
• sterilisation;
• environmental and process monitoring;
• aseptic process simulation;
• container-closure integrity; and
• the knowledge and behaviours of personnel.

The European Commission states that the manufacture of sterile products should be approached using the principles of quality risk management, with contamination risks understood and controlled across the complete manufacturing system.

This systems-based approach means that Annex 1 should not be treated simply as a checklist completed at the end of a sterile facility build. Its expectations should influence decisions from the beginning.

What is Quality by Design?

Quality by Design, or QbD, is a systematic approach that begins with predefined objectives and uses scientific understanding and risk management to design products and processes capable of delivering consistent performance.

ICH Q8 describes pharmaceutical development as the design of a quality product and manufacturing process that consistently delivers its intended performance.

Applied to sterile manufacturing, this means asking more than whether an individual room, item of equipment or process step meets a specification.

It means understanding:

• what could affect product sterility or quality;
• where contamination could be introduced;
• which process parameters and material attributes are critical;
• how risks can be eliminated or reduced through design;
• how remaining risks will be monitored and controlled; and
• how the overall system will continue to perform throughout its lifecycle.

The objective is not merely to respond effectively when something goes wrong. It is to design the process so that avoidable failures are less likely to occur.

Designing the facility around the process

A sterile facility should be designed around the intended manufacturing process, rather than forcing the process to fit a predetermined building layout.

Early decisions should therefore consider:

• the products and modalities to be manufactured;
• intended batch sizes;
• container formats and fill volumes;
• aseptic and terminal sterilisation pathways;
• equipment and single-use assemblies;
• personnel requirements;
• material transfer routes;
• waste flows;
• cleaning and disinfection processes;
• maintenance access; and
• future capacity or technology requirements.

The relationship between these elements matters.

A room may meet its environmental classification in isolation, but its design could still introduce operational risk if personnel and material routes are unnecessarily complex, if interventions are difficult to perform, or if equipment maintenance requires disruption to controlled areas.

Quality by Design encourages the project team to understand those interactions before the facility becomes operational.

Personnel and material flows

The movement of people, materials, components and waste is an important consideration in contamination control.

Facility flows should be logical, clearly defined and designed to minimise unnecessary crossover or movement through controlled areas.

This includes consideration of:

• personnel entry and gowning routes;
• raw material and component transfer;
• movement of sterilised items;
• product movement between processing stages;
• removal of waste;
• transfer of environmental-monitoring materials; and
• access for maintenance and engineering activities.

Poorly designed flows can create additional handling, increase the number of interventions and introduce avoidable contamination risks.

Where possible, risk should be reduced through physical separation, defined routes and process design rather than relying only on procedural controls.

Barrier technology and first-air protection

Annex 1 places significant emphasis on technologies that reduce direct human intervention within critical processing areas.

Barrier systems such as isolators can provide a high level of separation between operators and exposed sterile product. However, selecting an isolator is only one part of the solution.

The complete process must also be designed to maintain appropriate protection during:

• component loading;
• equipment assembly;
• sterile connections;
• filling;
• stoppering or closing;
• in-process sampling;
• environmental monitoring;
• line clearance; and
• removal of finished units.

The concept of first air is particularly important. Critical surfaces and exposed product should receive uninterrupted, appropriately filtered airflow wherever practicable.

Equipment, gloves, sensors and interventions must therefore be assessed for their potential to obstruct airflow or compromise the critical zone.

The strongest approach is to eliminate unnecessary interventions by design. Where interventions cannot be removed, they should be understood, standardised, assessed and incorporated into qualification and aseptic process simulation.

Closed processing and single-use technology

Closed systems and single-use technologies can support contamination control by reducing open handling, cleaning requirements and the number of product-contact assemblies that must be reused.

They may also offer advantages for flexible, multiproduct and early-phase manufacturing, including:

• reduced changeover requirements;
• lower cross-contamination risk;
• simplified product-contact pathways;
• faster campaign preparation;
• reduced cleaning-validation burden; and
• improved containment of valuable or sensitive drug substances.

However, single-use technology does not automatically create a closed or low-risk process.

The design and qualification of the complete assembly must consider:

• connection methods;
• filter configuration;
• integrity testing;
• extractables and leachables;
• supplier controls;
• sterilisation method;
• component compatibility;
• pressure limits;
• hold times; and
• the possibility of leaks or assembly damage.

The principle remains the same: technology should be selected because it controls an identified risk and supports the intended process—not simply because the technology is available.

Building a Contamination Control Strategy

The Contamination Control Strategy is one of the central concepts within the revised Annex 1.

A CCS should bring together the controls used to prevent microbial, particulate and endotoxin or pyrogen contamination. It should explain how those controls interact and why the overall strategy is capable of protecting the product.

A robust CCS may address:

• facility and process design;
• premises and equipment;
• personnel;
• utilities;
• raw materials and components;
• product containers and closures;
• supplier qualification;
• sterilisation processes;
• maintenance and preventative maintenance;
• cleaning and disinfection;
• environmental monitoring;
• process monitoring;
• prevention mechanisms;
• trend analysis;
• investigations;
• continuous improvement; and
• management review.

The value of the CCS lies in connecting these elements.

For example, environmental monitoring should not be viewed as a standalone activity intended to prove that a room is clean. It should be part of a broader control system that includes facility design, airflow, cleaning, operator behaviour, barrier technology and process understanding.

Monitoring detects performance. It does not replace effective contamination prevention.

Aseptic processing and terminal sterilisation

Where a product and its container-closure system can withstand terminal sterilisation, terminal sterilisation can provide a high level of sterility assurance.

For products that cannot tolerate the required terminal sterilisation conditions, aseptic processing may be necessary.

The selection should be based on scientific and product-specific evidence, including:

• thermal stability of the drug product;
• formulation characteristics;
• container and closure compatibility;
• potential impact on critical quality attributes;
• sterilisation-cycle development;
• bioburden considerations;
• filterability; and
• the intended clinical presentation.

The decision should be made early because it affects formulation development, component selection, process design, equipment requirements and the overall control strategy.

Eramol’s sterile manufacturing model has been designed to support both aseptic processing and moist-heat terminal sterilisation for suitable early-phase sterile injectable programmes. Its published sterile capabilities include isolator-based filling, closed-system processing and batch sizes of up to 10 litres.

Designing for early-phase sterile manufacturing

Early phase clinical programmes present a distinct set of manufacturing challenges.

Sponsors may have:

• limited quantities of drug substance;
• evolving formulations;
• incomplete process knowledge;
• small patient populations;
• changing clinical timelines;
• specialist container requirements; or
• products requiring complex handling.

A facility intended for early-phase sterile fill finish must therefore combine strong contamination control with operational flexibility.

Large-volume production lines may be well suited to mature commercial products, but can create inefficiencies when only a small number of clinical units is required. Excessive line priming, equipment hold-up, sampling or overage can consume a significant proportion of a scarce drug substance.

Quality by Design in this context includes consideration of both product protection and material efficiency.

Process development should examine:

• compounding-vessel hold-up;
• transfer-line volume;
• filter and tubing losses;
• filling-system priming;
• sampling requirements;
• destructive testing;
• overfill;
• rejects; and
• the number of units required for release, retention and stability testing.

Reducing avoidable material loss can be particularly important for biologics, advanced therapies, orphan-drug programmes and other products where drug substance is scarce, complex or expensive.

Designing quality into operations

A well-designed facility is only the starting point.

Once operational, the control strategy must be supported by:

• trained and qualified personnel;
• effective standard operating procedures;
• process qualification;
• cleaning and disinfection validation;
• environmental-monitoring programmes;
• aseptic process simulation;
• ongoing review of interventions;
• deviation and CAPA systems;
• change control;
• maintenance;
• data integrity; and
• periodic trend analysis.

Quality by Design should therefore continue throughout the facility lifecycle.

Operational data may identify changing risks, new process understanding or opportunities to improve controls. The CCS and associated risk assessments should evolve as that knowledge develops.

This is particularly important in a multiproduct environment, where different products, processes and presentations may introduce different contamination-control considerations.

Five practical lessons from applying Annex 1 and Quality by Design

Several practical principles can be taken from the design of a modern sterile fill-finish operation.

1. Start with the process, not the building

Understand what will be manufactured, how it will move through the facility and where the critical risks arise before finalising the layout.

2. Eliminate risk through design wherever possible

Physical separation, closed processing, barrier technology and simplified flows are generally stronger controls than procedures alone.

3. Consider the complete manufacturing system

Rooms, equipment, utilities, personnel, materials, monitoring and quality systems must work together. Optimising one element without understanding its effect on another can create hidden risks.

4. Design interventions out of the process

Human intervention is a major source of contamination risk in aseptic manufacture. The strongest intervention is often the one that is no longer required.

5. Treat the CCS as a living strategy

The Contamination Control Strategy should reflect current process knowledge and operational experience. It should be reviewed and improved as the facility, products and manufacturing processes develop.

From regulatory expectation to practical design

Annex 1 defines high expectations for the manufacture of sterile medicinal products, but successful implementation requires more than repeating the wording of the guidance.

Manufacturers must translate regulatory principles into practical decisions concerning facility layout, process design, technology selection, personnel behaviours and quality systems.

Quality by Design provides a framework for making those decisions systematically.

By identifying risks early, understanding how different controls interact and building contamination prevention into the process, manufacturers can create sterile operations that are more robust, more efficient and better able to protect both the product and the patient.

About the speaker

David Cox is Site Director at Eramol and leads the development and operation of the company’s Sevenoaks manufacturing facilities.

His presentation at CDMO Live Europe explored the practical considerations involved in applying EU GMP Annex 1 and Quality by Design principles during the design and development of a new sterile fill finish facility.

About Eramol

Eramol is a Qualified Person-led clinical manufacturing organisation providing integrated support from formulation and manufacturing through to packaging, labelling, QC testing, UK and EU QP release, storage and global distribution.

Its Sevenoaks sterile facility has been purpose-built to support flexible early-phase sterile injectable manufacturing, including aseptic fill finish and moist-heat terminal sterilisation.

Planning an early-phase sterile injectable programme?

Speak with Eramol about your product, batch requirements and clinical supply strategy.

Email: enquiry.uk@eramol.com
Learn more: [Sterile Fill Finish]
Explore: [Aseptic Processing] | [Terminal Sterilisation] | [End-to-End Sterile Manufacturing]

Based on a presentation by David Cox and technically reviewed by Eramol